Moody’s assigns Baa3 to Regeneron

Moody’s Investors Service said it assigned a Baa3 issuer rating to Regeneron Pharmaceuticals, Inc. The outlook is stable.

“Regeneron’s investment-grade rating reflects growing global scale, strong scientific expertise and an extremely conservative balance sheet, with very low financial leverage helping to mitigate business risks,” stated Michael Levesque, a Moody’s senior vice president, in a press release.

“These risks include high revenue concentration in Eylea, which faces biosimilar risk around 2024-2025, exposure to US drug pricing regulations, and pipeline execution risk,” Levesque said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.